Last reviewed · How we verify
Docetaxel/DDP
Docetaxel/DDP is a combination chemotherapy regimen that uses a taxane microtubule stabilizer paired with a platinum-based DNA crosslinking agent to inhibit cancer cell division and induce apoptosis.
Docetaxel/DDP is a combination chemotherapy regimen that uses a taxane microtubule stabilizer paired with a platinum-based DNA crosslinking agent to inhibit cancer cell division and induce apoptosis. Used for Advanced or metastatic non-small cell lung cancer, Gastric cancer, Head and neck cancer.
At a glance
| Generic name | Docetaxel/DDP |
|---|---|
| Sponsor | Sanofi |
| Drug class | Combination chemotherapy (taxane + platinum agent) |
| Target | Microtubules (docetaxel); DNA (cisplatin/DDP) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel (a taxane) stabilizes microtubules and prevents their disassembly, disrupting mitotic spindle formation and cell division. Cisplatin (DDP) forms DNA adducts and crosslinks, preventing DNA replication and transcription. The combination exploits complementary mechanisms to enhance cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Advanced or metastatic non-small cell lung cancer
- Gastric cancer
- Head and neck cancer
- Ovarian cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Peripheral neuropathy
- Nephrotoxicity
- Ototoxicity
- Alopecia
Key clinical trials
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer (PHASE3)
- Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery (PHASE2)
- Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer (PHASE2, PHASE3)
- A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer (PHASE2)
- Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer (PHASE2)
- Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |